Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024

• 2024

  Sign in to bookmark this resource.

  Sign in
• Heidi Moline; Ayzsa Tannis; Ariana Toepfer; John Williams; Julie Boom; Janet Englund
PMID: 38457312DOI: https://dx.doi.org/10.15585/mmwr.mm7309a4

---

Access Resources

• Journal ArticleEN

About

This study examines the effectiveness of nirsevimab, a monoclonal antibody, in preventing RSV-related hospitalizations in infants during their first RSV season. Conducted from October 2023 to February 2024, it found that nirsevimab was 90% effective. The median time from receiving the antibody to symptom onset was 45 days. The CDC recommends using either maternal RSV vaccination or infant receipt of nirsevimab for protection against severe RSV disease. Despite some limitations like low sample size and supply issues, the findings support current recommendations for preventing severe illness in infants.

---

Tags

Hazard: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Hospitalization; Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; United States; Respiratory Syncytial Virus Vaccines; Antibodies, Monoclonal, Humanized

Institutions: Centers for Disease Control and Prevention (CDC); Vanderbilt University; Seattle Children's Hospital; Baylor College of Medicine; University of Rochester

---

More like this

Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024 2024 · Centers for Disease Control and Prevention (CDC), U.S. Public Health Service, University of Rochester, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Vanderbilt University, Texas Children's Hospital, Baylor College of Medicine, University of Washington, University of Pittsburgh, Children's Mercy Kansas City Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024 2024 · Centers for Disease Control and Prevention (CDC), Maximus Federal Services, Inc., ICF Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2013 · Centers for Disease Control and Prevention (CDC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---